MY176510A - 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it - Google Patents

2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it

Info

Publication number
MY176510A
MY176510A MYPI20040938A MYPI20040938A MY176510A MY 176510 A MY176510 A MY 176510A MY PI20040938 A MYPI20040938 A MY PI20040938A MY PI20040938 A MYPI20040938 A MY PI20040938A MY 176510 A MY176510 A MY 176510A
Authority
MY
Malaysia
Prior art keywords
sulfonylamino
propyl
butyl
methoxypyridin
benz
Prior art date
Application number
MYPI20040938A
Inventor
Klaus Wirth Dr
Joachim Brendel Dr
Dr Heinz Goegelein Prof
Gert Ulrich Kuerzel Dr
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY176510A publication Critical patent/MY176510A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention relates to 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)propyl]benzamide of the formula I, and to its pharmaceutically acceptable salts, their preparation and use, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation or atrial flutters.
MYPI20040938A 2003-03-18 2004-03-17 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it MY176510A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (en) 2003-03-18 2003-03-18 2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3yl) -propyl] -benzamide, its use as a medicament and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
MY176510A true MY176510A (en) 2020-08-12

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20040938A MY176510A (en) 2003-03-18 2004-03-17 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it

Country Status (21)

Country Link
EP (1) EP1606237A1 (en)
JP (1) JP2006520343A (en)
KR (1) KR20050110681A (en)
CN (1) CN100361943C (en)
AR (1) AR043622A1 (en)
AU (1) AU2004222137A1 (en)
BR (1) BRPI0408441A (en)
CA (1) CA2519022A1 (en)
DE (1) DE10312073A1 (en)
HR (1) HRP20050815A2 (en)
MA (1) MA27749A1 (en)
MX (1) MXPA05009763A (en)
MY (1) MY176510A (en)
NO (1) NO20054472L (en)
NZ (1) NZ542476A (en)
PE (1) PE20050307A1 (en)
RS (1) RS20050690A (en)
RU (1) RU2333202C2 (en)
TW (1) TW200500342A (en)
WO (1) WO2004083157A1 (en)
ZA (1) ZA200506328B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (en) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Use of specific 2-substituted benzamides for treating and preventing cardiac insufficiency, especially where caused by diastolic dysfunction, act by inhibition of the Kv1.5 potassium channel
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (en) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
EP2435407B1 (en) * 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
DE10121003A1 (en) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
PE20050307A1 (en) 2005-06-08
DE10312073A1 (en) 2004-09-30
TW200500342A (en) 2005-01-01
HK1086819A1 (en) 2006-09-29
RU2005132163A (en) 2006-04-10
RS20050690A (en) 2008-04-04
WO2004083157A1 (en) 2004-09-30
RU2333202C2 (en) 2008-09-10
ZA200506328B (en) 2006-04-26
MA27749A1 (en) 2006-02-01
MXPA05009763A (en) 2006-01-27
CN100361943C (en) 2008-01-16
BRPI0408441A (en) 2006-04-04
JP2006520343A (en) 2006-09-07
NZ542476A (en) 2008-05-30
CN1756728A (en) 2006-04-05
AU2004222137A1 (en) 2004-09-30
KR20050110681A (en) 2005-11-23
AR043622A1 (en) 2005-08-03
NO20054472L (en) 2005-09-27
CA2519022A1 (en) 2004-09-30
HRP20050815A2 (en) 2006-09-30
EP1606237A1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
YU42503A (en) Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect
HRP20030448A2 (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
AR031430A1 (en) ORIS BISARILO COMPOUNDS, META-SUBSTITUTES, PROCEDURES FOR THEIR PREPARATION, ITS USE AS A MEDICINAL PRODUCT AS ALSO THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
TNSN03084A1 (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
WO2001064642A3 (en) Benzamides and related inhibitors of factor xa
UA83182C2 (en) Compounds effecting glucokinase
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
TNSN03134A1 (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
HK1042303A1 (en) New compounds
HK1052170A1 (en) Novel compounds inhibiting factor xa activity
IL188092A0 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
EP1284265A4 (en) Benzothiophene derivatives and medicinal use thereof
WO2002000166A3 (en) New compounds useful as antibacterial agents
SE0002729D0 (en) Novel compound form
MY176510A (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it
HK1042493A1 (en) New compounds
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.